Apr 18, 2022
Elaine Husni, MD, MPH, and Ana-Maria Orbai, MD, MHS, discuss the emerging and novel therapeutics in psoriatic arthritis and the impact that they will have on their patients.
Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/959157). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis https://www.rheumatology.org/Portals/0/Files/PsA-Guideline-2018.pdf
EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update https://ard.bmj.com/content/79/6/700.1
Treatment Guidelines in Psoriatic Arthritis https://academic.oup.com/rheumatology/article/59/Supplement_1/i37/5802853
Bimekizumab in Patients with Active Psoriatic Arthritis: Results From a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33161-7/fulltext